Triple threat: new combo shows promise against tough breast cancer
NCT ID NCT01730833
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tested a combination of two targeted antibodies (pertuzumab and trastuzumab) plus a chemotherapy drug (nab-paclitaxel) in 63 patients with HER2-positive advanced breast cancer. The goal was to see how well the drugs work together to stop tumor growth and improve survival. The study included patients with stage II to IV disease, and measured how long they lived without their cancer getting worse.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pertuzumab, trastuzumab, and nab-paclitaxel
- What this could lead to
- If successful, this combination could offer a more effective way to shrink tumors and delay progression in HER2-positive advanced breast cancer.
- What could go wrong
- This is a small, single-group phase II trial, so results may not apply broadly. Side effects from chemotherapy and antibodies can be serious, and the treatment may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Antelope Valley
Lancaster, California, 93534, United States
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
City of Hope- South Pasadena Cancer Center
South Pasadena, California, 91030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer
- Can a new drug outsmart resistant breast cancer?
- Can a new targeted drug outperform the current standard for HER2-Positive breast cancer?